Caffeic acid, a dietary polyphenol, as a promising candidate for combination therapy
Abstract Increased effectiveness and decreasing toxicity are prime objectives in drug research. Overwhelming evidence suggests the use of appropriate combination therapy for the better efficacy of drugs owing to their synergistic profile. Dietary active constituents play a major role in health outcomes. Therefore, it is possible to increase the effectiveness of the drug by combining contemporary medication with active natural/semi-synthetic constituents. One such dietary constituent, caffeic acid (CA), is a by-product of the shikimate pathway in plants and is a polyphenol of hydroxycinnamic acid class. Extensive research on CA has proposed its efficacy against inflammatory, neurodegenerative, oncologic, and metabolic disorders. The synergistic/additive effects of CA in combination with drugs like caffeine, metformin, pioglitazone, and quercetin have been reported in several experimental models and thus the present review is an attempt to consolidate outcomes of this research. Multi-target-based mechanistic studies will facilitate the development of effective combination regimens of CA..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Chemické zvesti - 76(2021), 3 vom: 05. Nov., Seite 1271-1283 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maity, Swastika [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Bioactive metabolites |
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1007/s11696-021-01947-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2129445373 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2129445373 | ||
| 003 | DE-627 | ||
| 005 | 20230505222550.0 | ||
| 007 | tu | ||
| 008 | 230505s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11696-021-01947-7 |2 doi | |
| 035 | |a (DE-627)OLC2129445373 | ||
| 035 | |a (DE-He213)s11696-021-01947-7-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.00 |2 bkl | ||
| 100 | 1 | |a Maity, Swastika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Caffeic acid, a dietary polyphenol, as a promising candidate for combination therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Abstract Increased effectiveness and decreasing toxicity are prime objectives in drug research. Overwhelming evidence suggests the use of appropriate combination therapy for the better efficacy of drugs owing to their synergistic profile. Dietary active constituents play a major role in health outcomes. Therefore, it is possible to increase the effectiveness of the drug by combining contemporary medication with active natural/semi-synthetic constituents. One such dietary constituent, caffeic acid (CA), is a by-product of the shikimate pathway in plants and is a polyphenol of hydroxycinnamic acid class. Extensive research on CA has proposed its efficacy against inflammatory, neurodegenerative, oncologic, and metabolic disorders. The synergistic/additive effects of CA in combination with drugs like caffeine, metformin, pioglitazone, and quercetin have been reported in several experimental models and thus the present review is an attempt to consolidate outcomes of this research. Multi-target-based mechanistic studies will facilitate the development of effective combination regimens of CA. | ||
| 650 | 4 | |a Caffeic acid | |
| 650 | 4 | |a Combination therapy | |
| 650 | 4 | |a Caffeine | |
| 650 | 4 | |a Metabolic disorders | |
| 650 | 4 | |a Bioactive metabolites | |
| 700 | 1 | |a Kinra, Manas |4 aut | |
| 700 | 1 | |a Nampoothiri, Madhavan |4 aut | |
| 700 | 1 | |a Arora, Devinder |4 aut | |
| 700 | 1 | |a Pai, K. Sreedhara Ranganath |4 aut | |
| 700 | 1 | |a Mudgal, Jayesh |0 (orcid)0000-0001-8190-7031 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemické zvesti |d Versita, 1947 |g 76(2021), 3 vom: 05. Nov., Seite 1271-1283 |w (DE-627)129938920 |w (DE-600)391411-2 |w (DE-576)015500659 |x 0037-6906 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2021 |g number:3 |g day:05 |g month:11 |g pages:1271-1283 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11696-021-01947-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 35.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 76 |j 2021 |e 3 |b 05 |c 11 |h 1271-1283 | ||